To determine whether the suppression of IL-4 and IL-21 induced downstream pathways could serve as a strategy to treat autoimmune diseases, we used three JAK inhibitors to suppress IL-4/STAT6 and IL-21/STAT3 activation in anti-IgM-treated Ramos cells. This evidence concerns the gene STAT6 and autoimmune disease.